PAIN: A Project Assessing the Impact of a Novel Cannabinoid Product

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Chronic Pain

In brief

This study is a clinical trial of a high-cannabidiol (CBD) sublingual product compared to placebo for 9 weeks in patients with chronic pain conditions. The study will assess the impact of CBD on chronic pain symptoms, conventional medication use, clinical state, quality of life, cognition, and biomarkers.

Key facts

Study ID: NCT03984565
Run by: Staci Gruber, Ph.D.
People needed: 25
Starts: 2024-06-27
Expected to finish: 2026-09-01
Last updated by the study team: 2026-03-30

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject has provided informed consent
Subject is 21 or older
Subject is fluent in English
Subject endorses a musculoskeletal chronic pain condition including, but not limited to, chronic pain due to injury, arthritis (including osteoarthritis and rheumatoid arthritis), bursitis, etc.

You may not qualify if…

Non-fluent English speakers
Estimated IQ < 75
A history of head injury or loss of consciousness greater than 5 minutes
Currently uses CBD products regularly
Female subjects will be excluded if they have a positive urine pregnancy test, are trying to become pregnant, or are currently breastfeeding
Presence of a serious or unstable medical illness, including liver, kidney, or cardiovascular disease (hyper/hypotension, cardiac disorders), or neurological disorder (including seizure disorder)
Primary neuropathic pain or cancer-related pain; patients experiencing neuropathic pain secondary to musculoskeletal pain will be allowed to enter the study
Disclosure of a genetic polymorphism affecting CYP2C9 function

Where it is running

McLean Hospital — Belmont, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.